Incidence of Respiratory Tract Infection Following the Use of Clozapine among Patients admitted to Prasrimahabhodi Psychiatric Hospital
Article Sidebar
Main Article Content
Abstract
Objectives: To determine the incidence of respiratory tract infection (URI) and its risk factors following the use of clozapine among patients admitted to Prasrimahabhodi Psychiatric Hospital. Methods: This study was a retrospective cohort study. The data were retrospectively collected from medical records of inpatients diagnosed with schizophrenia who had received clozapine from January 1, 2021 to December 31, 2022. Cox proportional hazards regression was used to assess the relationship of adverse events, concomitantly used medication, chronic diseases, and URI in patients with clozapine use. Results: Among 350 eligible patients with clozapine use, 51 patients developed URI with the incidence rate of 1.544 per 1,000 person-days. There were four patients with URI progression to pneumonia with the incidence rate of 0.121 per 1,000 person-days. Factors significantly associated with an increased risk of URI in patients with clozapine use included clorazepate use (HRadj=5.51; 95%CI 1.29-23.51, P=0.021), lorazepam use (HRadj=2.00; 95% CI 1.05-3.79, P=0.034), having hypertension as comorbidity (HRadj=5.65; 95%CI 1.32-24.19, P=0.019) and having diabetes as comorbidity (HRadj=2.02; 95%CI 1.06-3.85, P=0.031). Conclusion: Inpatients with clozapine use may have an increased risk of URI if they also receive lorazepam or clorazepate or having diabetes mellitus or hypertension as comorbidities. Health professionals should monitor these groups of patients to prevent them from developing URI.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Kanjanasilp J, Ploylearmsang C. A short term outcomes of pharmaceutical care in Thai patients with schizophrenia: a randomized controlled trial. Songklanakarin J Sci Technol 2016; 38: 189-97.
Sathienluckna T. Pharmacotherapy of schizophrenia [online]. 2017[cited Mar 13, 2023]. Available from: ccpe.pharmacycouncil.org/index.php?option=article_detail&subpage=article_detail&id=218.
Mortimer A, Singh P, Shepherd C, Puthiryackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psy choses 2010; 4: 49-55.
Alvarez PA, Pahissa J. QT alterations in psychophar macology: proven candidates and suspects. Curr Drug Saf 2010; 5: 97-104.
De Leon J, Ruan C-J, Verdoux H, Wang C. Cloza- pine is strongly associated with the risk of pneumonia and inflammation. Gen Psychiatr 2020; 33: 25-36.
De Leon J, Ruan C-J, Schoretsanitis G, De las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psycho som 2020; 89: 200-14.
Dzahini O, Singh N, Taylor D, Haddad P. Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol 2018; 32: 1167-81.
Cicala G, Barbieri MA, Spina E, de Leon J. A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Rev Clin Pharmacol 2019; 12: 219-34.
Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine. New York, USA: Mcgraw-hill; 2015.
Chang C-K, Chen P-H, Pan C-H, Su S-S, Tsai S-Y, Chen C-C, et al. Antipsychotic medications and the progression of upper respiratory infection to pneumonia in patients with schizophrenia. Schizophr Res 2020; 222: 327-34.
Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000; 1482: 157-71.
Israili Z, Dayton P. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33: 161-235.
Stoecker ZR, George WT, O’Brien JB, Jancik J, Colon E, Rasimas JJ. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol 2017; 32: 155-60.
Espnes KA, Heimdal KO, Spigset O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monit 2012; 34: 489-92.
Leung JG, Nelson S, Takala CR, Gören JL. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann Pharmacother 2014; 48: 801-5.
Osborne IJ, McIvor RJ. Clozapine-induced myoclo- nus: a case report and review of the literature. Ther Adv Psychopharmacol 2015; 5: 351-6.
Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007; 52: 457-63.
Clark SR, Warren NS, Kim G, Jankowiak D, Schubert KO, Kisely S, et al. Elevated clozapine levels associated with infection: a systematic review. Schizophr Res 2018; 192: 50-6.
Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62: 15-26.
Department of Disease Control. Epidemiological surveillance report 2019. Nonthaburi: Ministry of public health, Thailand; 2019.
Cheng SY, Chen WY, Liu HC, Yang TW, Pan CH, Yang SY, et al. Benzodiazepines and risk of pneumonia in schizophrenia: a nationwide case-control study. J Psychopharmacology (Berl) 2018; 235: 3329-38.
Zekavat SM, Honigberg M, Pirruccello JP, Kohli P, Karlson EW, Newton-Cheh C, et al. Elevated blood pressure increases pneumonia risk: epidemiological association and mendelian randomization in the UK Biobank Med 2021; 2: 137-48.
Abdelmawla N, Ahmed MI. Clozapine and risk of pneumonia. Br J Psychiatry 2009; 194: 468-9.
